Pharma and Biotech
Notice of Extraordinary General Meeting | 22-Nov-2024 | 12:49 | RNS |
IRB Approval for Phase I Clinical Trial | 22-Nov-2024 | 07:00 | RNS |
Institutional Investment | 11-Nov-2024 | 07:00 | RNS |
Schedule for Phase I Clinical Trial Opening | 30-Oct-2024 | 07:00 | RNS |
Strategic Investment from Prevail Partners, LLC | 02-Oct-2024 | 11:19 | RNS |
Half-year Report | 27-Sep-2024 | 07:00 | RNS |
FLT3 Assay Ready for Phase I Trials at MD Anderson | 09-Sep-2024 | 07:00 | RNS |
CDX Development Update | 02-Sep-2024 | 07:00 | RNS |
Presentation at CBD S&T Conference | 28-Aug-2024 | 07:00 | RNS |
Result of Annual General Meeting | 27-Jun-2024 | 16:39 | RNS |
Operations Update | 17-Jun-2024 | 07:00 | RNS |
Posting of Annual Report & Notice of AGM | 03-Jun-2024 | 07:00 | RNS |
Final Results | 25-Apr-2024 | 07:00 | RNS |
Total Voting Rights | 28-Mar-2024 | 07:00 | RNS |
Placing to Raise US$4.2 million | 29-Feb-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 1.20p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 3.96 |
52 Week Low | 0.88 |
Volume | 0 |
Shares Issued | 1,401.82m |
Market Cap | £16.82m |
Beta | 0.73 |
RiskGrade | 340 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
You are here: research